 |
|
Hope for patients with COPD
August 15, 2008For the first time, a drug therapy appears to reduce lung function loss in patients with moderate to severe chronic obstructive pulmonary disease (COPD), according to the results of a randomized, double-blind, placebo-controlled trial in 42 countries.
The Toward a Revolution in COPD Health (TORCH) study investigated the effects of combined salmeterol, a ß-agonist, and fluticasone propiniate, an inhaled cortical steroid, either alone or in combination, on mortality, exacerbations, health-related quality of life and rate of decline in lung function as measure by forced expiratory volume in one second (FEV1) in patients with COPD.
The results are published in the second issue for August of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.
"Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline on FEV1 in patients with moderate to severe COPD, thus slowing disease progression," wrote Bartolome R. Celli, M.D., lead author of the study and professor at Tufts University School of Medicine. "To date, smoking cessation is the only intervention that has conclusively been shown to alter the rate of decline in FEV1," remarked Dr. Celli. This is the first demonstration of an effective pharmacothrerapy in COPD.
The TORCH study randomized more than 6,000 patients with moderate to severe COPD from 42 countries to receive either salmeterol (SAL; 50 g), fluticasone propionate (FP; 500 g), the two in combination (SFC; 50/500g), or placebo. After baseline FEV1 was recorded, patients were re-evaluated every 24 weeks to determine the rate of decline in FEV1.
"The rate of decline in FEV1 was slowest in patients on SFC and fastest in those randomized to the placebo arm," wrote Dr. Celli. "From week 24 onward, the adjusted rate of decline in FEV1 was 39ml/year for SFC, 42 ml/year for both SAL and FP and 55 ml/year for placebo."
Although the study was not formally powered to detect differences in rate of decline of FEV1, the results were highly significant (p<0.001.) The rate of decline in treatment groups was similar across a number of variables, including sex, age, ethnicity and body mass index. Furthermore, the slower rate of decline in FEV1 appeared to be associated with a lower risk of exacerbation.
"Although treatment did not abolish the accelerated decline in lung function [that occurs with COPD], it did ameliorate it substantially," wrote Dr. Celli, while noting that "the mechanism responsible for the effect on rate of decline is not clear, as all treatments have potentially significant nonbronchodilator effects." Clarifying those mechanisms is the goal of the next phase of the research, with the comparison between a long-acting bronchodilator drug and placebo with respect to FEV1 decline.
In the meantime, "the TORCH study brings some clarity to the treatment picture and provides some hopeful signs for patients with COPD," wrote Samy Suissa, Ph.D., of McGill University, in the accompanying editorial. "This study also demonstrates that no treatment [placebo] is not an option for patients with moderate to severe COPD."
American Thoracic Society
"Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline on FEV1 in patients with moderate to severe COPD, thus slowing disease progression," wrote Bartolome R. Celli, M.D., lead author of the study and professor at Tufts University School of Medicine. "To date, smoking cessation is the only intervention that has conclusively been shown to alter the rate of decline in FEV1," remarked Dr. Celli. This is the first demonstration of an effective pharmacothrerapy in COPD.
The TORCH study randomized more than 6,000 patients with moderate to severe COPD from 42 countries to receive either salmeterol (SAL; 50 g), fluticasone propionate (FP; 500 g), the two in combination (SFC; 50/500g), or placebo. After baseline FEV1 was recorded, patients were re-evaluated every 24 weeks to determine the rate of decline in FEV1.
"The rate of decline in FEV1 was slowest in patients on SFC and fastest in those randomized to the placebo arm," wrote Dr. Celli. "From week 24 onward, the adjusted rate of decline in FEV1 was 39ml/year for SFC, 42 ml/year for both SAL and FP and 55 ml/year for placebo."
Although the study was not formally powered to detect differences in rate of decline of FEV1, the results were highly significant (p<0.001.) The rate of decline in treatment groups was similar across a number of variables, including sex, age, ethnicity and body mass index. Furthermore, the slower rate of decline in FEV1 appeared to be associated with a lower risk of exacerbation.
"Although treatment did not abolish the accelerated decline in lung function [that occurs with COPD], it did ameliorate it substantially," wrote Dr. Celli, while noting that "the mechanism responsible for the effect on rate of decline is not clear, as all treatments have potentially significant nonbronchodilator effects." Clarifying those mechanisms is the goal of the next phase of the research, with the comparison between a long-acting bronchodilator drug and placebo with respect to FEV1 decline.
In the meantime, "the TORCH study brings some clarity to the treatment picture and provides some hopeful signs for patients with COPD," wrote Samy Suissa, Ph.D., of McGill University, in the accompanying editorial. "This study also demonstrates that no treatment [placebo] is not an option for patients with moderate to severe COPD."
American Thoracic Society
Science News and Science Current Events Tag Cloud
This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size.
Caloric Restriction Saliva Salmonella Hearing Solar Cell Flooding New Species Aphids Sleep problem Cryoablation Phytophthora Yeast Cells Diatoms Pregnancy Overweight Methane Metformin Enzyme Lou Gehrig's disease Lung Transplant Fear HPV vaccine Shark Attack Narcolepsy Quantum Physics
See More: Science News Tags
Chronic Obstructive Pulmonary Disease Current Events and Chronic Obstructive Pulmonary Disease News RSSGroup Health Cooperative shows investing in more primary care pays for itself
An evaluation of recent innovations in delivering primary care at a Group Health Cooperative medical center shows significant success and rapid return on investment.
Top notch decisions in the developing airways bring insights into lung disease
In the normal lung, the airways are lined by a balanced mixture of ciliated, secretory and neuroendocrine cells which perform functions as diverse as air humidification, detoxification, and clearance of environmental particles.
Investigation finds that cigarette smoking does not affect everyone in same way
Cigarette smoking induced COPD, or chronic obstructive pulmonary disease, is a disease that results in severe breathing difficulty.
Lifestyle program for patients with COPD is health and cost effective
Patients with moderate COPD were randomized to receive "usual care" or to undergo an interdisciplinary, community-based program (INTERCOM) that offered an intensive lifestyle moderation phase of four months, during which patients were instructed in detail to perform two 15-minute intervals of pleasurable walking or cycling, and offered instruction in other lifestyle changes such as nutrition and smoking cessation.
Early exposure to tobacco smoke may lead to early emphysema later
Chronic exposure to tobacco smoke in childhood may contribute to early emphysema later in life, according to new research.
Potential Lung Disease Biomarkers Yield Clues to COX-2 Inhibitor Side Effects
In searching for a simple way to identify individuals with smoking-related lung injury, scientists at Weill Cornell Medical College have stumbled upon a potential explanation for why the class of pain-relievers known as COX-2 inhibitors increases the risk of heart problems among users.
Different treatment options in chronic coronary artery disease
Sometimes cardiologists and cardiac surgeons can agree! There is often disagreement between the professions of cardiology and cardiac surgery about the proper therapy for coronary artery disease (CAD)-and this can harm the patient.
Marijuana smoking increases risk of COPD for tobacco smokers
Smoking both tobacco and marijuana increases the risk of respiratory symptoms and chronic obstructive pulmonary disease (COPD). Smoking only marijuana, however, was not associated with increased risks.
Cigarette smoke may alter immune response in COPD exacerbations
Smoking cigarettes is not only the principle cause of chronic obstructive pulmonary disease (COPD), but it may change the body's immune responses to bacteria that commonly cause exacerbations of the disease, according to new research in a mouse model.
Supervised exercise therapy can lead to improvements in COPD symptoms
Those suffering from chronic obstructive pulmonary disease (COPD) often complain that exercise is too exhausting and leaves them breathless.
More Chronic Obstructive Pulmonary Disease Current Events and Chronic Obstructive Pulmonary Disease News Articles
 |
Chronic Obstructive Pulmonary Disease by Steve Rennard (Editor), Bartolome Celli (Editor), Klaus Rabe (Editor) The only international clinical textbook for COPD – one of the top 5 causes of death and disability worldwide The only COPD textbook to include the latest national and international guidelines and the newer therapeutic agents in COPD treatment International team of contributors covers all aspects of COPD – from physiology and epidemiology to diagnosis and treatment Everything the busy physician needs to understand, diagnose and treat the COPD patient: - Structure and physiology of the respiratory system |
 |
Handbook of Chronic Obstructive Pulmonary Disease by Taylor & Francis The medical literature addresses chronic obstructive pulmonary disease (COPD), but this text focuses on the most salient aspects of the disease and brings those into a single reference source. Handbook of Chronic Obstructive Pulmonary Disease begins with clear classifications of COPD symptoms and defines the full pathology. The editors then concentrate on management--the best approach, medications, prevention and methods for dealing with complications. That concentration, along with the concise layout and explanations, makes this guide extremely practical. It is ideal for the clinician who attends to COPD patients. |
 |
FlameEz-Lung, 60 Capsules/Bottle by FlameEz Chronic Obstructive Pulmonary Disease (COPD) is progressive inflammatory disease affecting the respiratory tract and the lungs. Inflammation causes destruction of airways and lung tissues. If inflammation persists, the damage to the airways and lungs may not be reversed. Recent studies also suggest that inflammation is a critical component in lung cancer development, progression and metastasis. Inflammation induces the release of a variety of inflammatory cytokines that cause oxidative damage, DNA mutation, and cell transformation. Inflammation also plays a key role in survival and expansion of tumor cells. Since tumor cells produce various substances that attract inflammatory cells, which are indispensable participants in tissue disruption and metastasis, inflammation has been described... |
 |
Chronic Obstructive Pulmonary Disease: Cause by GeneEd E-Learning Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation that cannot be fully reversed and by abnormal inflammation, due to chronic inhalation of particles or noxious gas. Symptoms rarely manifest in patients younger than age 40; after onset, however, respiratory function declines precipitously over several years. This course introduces the pathophysiology and epidemiology of COPD. eTextBooks from GeneEd are self-paced, multimedia courses designed for nurses (RNs), doctors (MDs and PhDs), clinical research associates (CRAs and monitors), clinical research coordinators (CRCs), investigators, researchers, other healthcare professionals, and patients. |
|
Pathophysiology of Chronic Obstructive Pulmonary Disease [VHS] Starring: Lippincott | |
 |
Life and Breath: Preventing, Treating and Reversing Chronic Obstructive Pulmonary Disease by Neil Schachter (Author) The fourth leading cause of death in the United States, COPD, or chronic obstructive pulmonary disease, affects an estimated 35 million Americans. Yet only half are aware that they are seriously ill. Life and Breath, by Dr. Neil Schachter, is the first book that alerts people to their risks for COPD and explains the steps they need to take to prevent the development of this debilitating and often fatal lung disease. Life and Breath begins witha quick quiz to rate your risk for COPD. It explains the steps of a complete pulmonary work-up and teaches you about the painless, inexpensive six-second test that can save your life. We all know that diet, exercise, and environmental changes can reduce the risk of heart disease and some types of cancer. Now, for the first time, Life... |
 |
Chronic Respiratory Disorders (118) DVD Two part series focuses on respiratory conditions which have long term implications of the health of those affected - COPD and Cystic Fibrosis. Using scenarios, graphics, art and animation the pathophysiology, risk factors, symptoms for each are discussed and illustrated. The CD version is interactive. Throughout there are screens with questions about the material covered followed by correct answers and rationales. |
 |
COPD Awareness Ribbon Mouse Pad by MyHeritageWear.com The COPD Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the COPD Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your COPD Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Atlas of Chronic Obstructive Pulmonary Disease by Taylor & Francis This book contains approximately 120 detailed schematic diagrams that detail disease progression, diagnosis, and treatment; clinical photographic material that illustrates visual diagnostic cues; and figures and flow diagrams that present a concise review of the epidemiology, diagnosis, and management of the disease. The authors cover the drugs recommended for treatment, their mode of action, potential side effects, and recommended uses. They discuss the management of both stable COPD and exacerbations of COPD, differential diagnoses and asthma, management in general practice and in hospitals, and future trends in therapy, such as new bronchodilators and anti-inflammatory treatments. |
|
|
Chronic Respiratory Disorders (118) CD-ROM by Concept Media, a division of Jobson Medical Information LLC 5 CD series including these programs: [118.1] Chronic Obstructive Pulmonary Disease; [118.2] Cystic Fibrosis; |
| © 2009 BrightSurf.com |